The limited effect of information on Israeli pregnant women at advanced maternal age who decide to undergo amniocentesis by Julia Grinshpun-Cohen et al.
Israel Journal of
Health Policy Research
Grinshpun-Cohen et al. Israel Journal of Health Policy Research  (2015) 4:23 
DOI 10.1186/s13584-015-0019-6ORIGINAL RESEARCH ARTICLE Open AccessThe limited effect of information on Israeli
pregnant women at advanced maternal
age who decide to undergo amniocentesis
Julia Grinshpun-Cohen1,2*, Talya Miron-Shatz3,4, Michal Berkenstet1 and Elon Pras1,2Abstract
Background: A primary goal of amniocentesis is the detection of trisomy 21 (Down syndrome- DS) in the fetus.
This procedure involves a small risk of miscarriage. As the risk of DS increases with maternal age, screening tests
(maternal serum triple test and others) and age are used to generate a risk assessment, and amniocentesis is offered
to women with high risk. In Israel, amniocentesis is government funded for women of advanced maternal age
(AMA, i.e., ≥35 years), even if their risk assessment is low.
The purpose of this study was to explore the reasons AMA women undergo amniocentesis, their knowledge about
risk estimates, and to evaluate whether their decision is informed.
Methods: Shortly after undergoing amniocentesis, 42 consecutive women without a medical indication for
amniocentesis other than age, completed a questionnaire that assessed their knowledge and opinions regarding
screening tests, pregnancy termination, amniocentesis risks and the factors that affected their decision.
Results: Women rarely deliberated before undergoing amniocentesis. One third of those who had the screening
test did not wait for the results before undergoing amniocentesis. Only one third of those who received the
screening results remembered their risk estimation before going ahead with amniocentesis. Almost half (41 %) cited
“age” as their main reason for undergoing amniocentesis, though only 44 % of these women could recall their age
related DS risk. Sixty percent estimated their DS risk as low or very low but still had amniocentesis. Most
participants (74 %) stated that they would consider termination of the pregnancy if the fetus was diagnosed with
an intellectual deficit.
Conclusions: These results cast doubt on whether AMA women’s decision to undergo amniocentesis is based on
risk estimates, as women seem to disregard risk estimates, and sometimes not even wait for them when making
the decision. The policy of funding amniocentesis solely on the basis of age may have led to the conception that
being over 35 alone is sufficient reason to undergo amniocentesis. This finding should inform policy makers, as it
raises questions about the link between public funding and the choices of individual women, and has implications
for healthcare expenditures.
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Medicine increasingly emphasizes patient participation
and informed choice in decision making, which some-
times lead to financial savings [1]. O’Connor and
O’Brien-Pallas state that “An effective decision is one
that is informed, consistent with the decision maker’s
values and behaviorally implemented” [2]. This study set
out to examine the degree to which the decision of
Israeli women who are AMA (advanced maternal age,
i.e., ≥35 year old) to undergo amniocentesis is informed
by risk estimates and the factors that affect this decision.
Amniocentesis is an invasive procedure performed dur-
ing pregnancy to determine (among other things) whether
the fetus has Down syndrome (Trisomy 21- DS). The risk
of fetal DS increases with increased maternal age, from
1:1600 at age 20 to 1:30 at age 45, with a risk of approxi-
mately 1:350 at age 35 and 1:100 at age 40 [3, 4]. Screen-
ing for DS in maternal serum – such as the triple screen
performed in the second trimester that includes measure-
ment of AFP (Alfa Fetoprotein), HCG (Human Chorionic
Gonadotropin) and UE3 (Unconjugated Estriol) – facili-
tates better risk estimates and identification of subgroups
of women considered to be at higher risk for whom am-
niocentesis is indicated. Conversely, DS screening also fa-
cilitates identification of those at low risk for DS for
whom amniocentesis is not recommended [5]. Amniocen-
tesis is associated with an increased risk of miscarriage.
The exact magnitude of this additional risk is equivocal
and is estimated to be in the range of 1:100–1:1600 [6–8].
While various risk estimates are used by physicians and
counselors (in Sheba Medical Center 1:1000 is the risk of
miscarriage commonly conveyed during counseling), the
Israeli Medical Association consent form used by all
Israeli medical facilities gives the risk of miscarriage as
1:200. Thus, the decision to perform the procedure can
also lead to negative consequences.
Since 1980, amniocentesis has been funded by the
Israeli Ministry of Health for women who are older than
37 years at the onset of pregnancy regardless of other in-
dications [9], and since 1993, this funding has been
expanded to all women ages 35 and up [10, 11]. Add-
itionally, amniocentesis is funded by the Ministry of
Health for women younger than 35, whenever there are
abnormal ultrasound findings or relevant family history,
and by the health insurance organizations when there is
a high risk based on screening tests [12, 13].
During the period of 2002–2006, almost 47,500
women in Israel had amniocentesis for the sole indica-
tion of AMA. In 2006, 11,131 amniocentesis procedures
were performed in Israel due to AMA, while only 2355
procedures were performed for all other medical indica-
tions, such as ultrasound findings or high risk for a gen-
etic disease (not including high DS risk) [14]. Compared
with other western countries, Israeli women tend toperform more tests during pregnancy including genetic
carrier screening, ultrasound scans and biochemical
screening for DS [15]. Our previous work has shown
that, in a small sample of educated, mostly secular AMA
women, the vast majority (87 %) had amniocentesis;
many of them performed the test before receiving their
DS screening results [16]. Based on the latest survey of
the Israeli Ministry of Health, among Jewish women
under age 35, 62 % had triple test screening and 11 %
had amniocentesis [17]. However, among Jewish AMA
women, 47 % had amniocentesis (and 64 % had triple
test screening). Among AMA women that did not have
amniocentesis, 83 % said that they were referred for it
[17]. This survey included religious women who are
known to perform fewer tests,
Studies from the Netherlands, Australia and Canada
showed that only a fraction of women reached an in-
formed decision regarding screening for DS [18–20].
These studies suggest that in order to promote a higher
rate of informed decisions, counselees need professional
help in obtaining the necessary information and explor-
ing their options. Furthermore, the studies propose that
risk perception is complicated and that risk estimates
are often not directly integrated into the decision mak-
ing process. In a study conducted before screening for
DS was available, French et al. found no relationship be-
tween knowledge and the decision to undergo amnio-
centesis in a sample of highly educated women [21].
Even when DS screening was offered, it was noted that
pregnant AMA women’s decision regarding amniocen-
tesis may not always correlate clinically with DS screen-
ing results [22], though some researchers have found
that screening for DS decreased amniocentesis uptake
among AMA women [23, 24].
If the decision to undergo amniocentesis is not fully
informed by objective risk estimates, and there is no
clear association between DS screening results and
women’s decision to undergo amniocentesis, what drives
the decision? Previous work has suggested several fac-
tors that predict test uptake: positive attitudes toward
prenatal diagnostic tests, perception of prenatal diagnos-
tic tests as reliable, and requests for more scientific in-
formation [25]. A study conducted in Israel found that
use of amniocentesis by low risk women was associated
with older age and receipt of more information about
the test [26]. Others have shown that negative percep-
tions of having a child with DS had a more significant
influence on decisions than the numeric probability of
having such a child, as indicated by screening results
[27]. In a previous study, we found that a priori opinions
regarding the relationship between age and amniocen-
tesis risk, as well as termination tolerance, affected the
decision more than test results obtained during preg-
nancy [28]. Additionally, Bryant et al. have shown that
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cantly associated with uptake of screening, as well as
with intention to undergo amniocentesis and willingness
to terminate an affected pregnancy [29, 30]. In sum, the
relationship between screening tests and amniocentesis
uptake is complex, and the decision to undergo amnio-
centesis is often not based on medical or statistical infor-
mation, thereby raising the question of what drives the
decision and how informed it is.
The objectives of the current study were to outline the
factors that affect Israeli AMA women’s decision process
regarding amniocentesis and to explore whether the de-
cision is informed by knowledge, is carried out by con-
sidering the risks, and is aligned with a willingness to
terminate a pregnancy if a problem is detected with the
fetus. Degree of deliberation was also used as an indirect
measure of informed choice. It has been previously
shown that deliberation can be used to measure decision
quality [31], and interventions that help people deliber-
ate, promote a better decision process [32]. In addition
to a measure of informed choice, degree of deliberation
was also examined in terms of its association with
decision-relevant factors. Based on our previous work
[16], we expected women to have a low level of know-
ledge regarding the many tests they had during preg-
nancy. Since knowledge is a central component of
informed choice, their decision was predicted not to be
fully informed. Previous studies did not extensively ad-
dress variables like objective risk perception and termin-
ation tolerance. These were used here to explore
whether the decision is concordant with personal (sub-
jective) perceptions and beliefs, even if it is not fully
informed.Methods
Procedure
The study was conducted at the Sheba Medical Center
after being approved by the Sheba IRB. For several days,
all AMA women who had amniocentesis were approached
after the procedure and asked to participate. Those who
agreed signed a consent form and completed a 30-
question questionnaire that took approximately 15 min.
Initially, fifty participants were recruited of the 57 who
were approached; thus participation rate was 87 %. Seven
participants were later excluded due to abnormal screen-
ing results or ultrasound findings, and one was excluded
due to twin pregnancy. Thus, 42 AMA participants who
decided to undergo amniocentesis without a medical indi-
cation were interviewed.Participants
All 42 participants were Hebrew speakers. The average
age was 37.8 years (range 35–42, SD = 1.94). Almost allparticipants (n = 38, 90 %) had previous children, and
eight (19 %) had undergone fertility treatments for the
current pregnancy. Participants were highly educated: 23
(55 %) had a college degree and 17 of those (40 %), had
also completed post-graduate degrees (MS, MD or PhD).
Most participants (n = 34, 81 %) described themselves as
secular, six (14 %) as traditional and two (5 %) as
religious.Measures
1. Knowledge score - a 0-4 score that captured recall of
the age-related and amniocentesis-related risk estimates
from the first trimester screening and second trimester
screening.
2. Age-risk perception - the subjective age-related DS
risk, as scored on a 5 point scale (very low-1 to very
high -5).
3. Amniocentesis risk perception - defined depending
upon whether the woman perceived the risk associated
with amniocentesis as (1) low, (2) medium or (3) high.
4. Deliberation level - whether the woman reported
having much (score of 2), some (score of 1) or no
(score of 0) deliberation regarding her decision to
undergo amniocentesis.
5. Pregnancy termination tolerance - was a 0-5 score
defined as a cumulative number of “yes” answers
(coded as “1”) to the question of termination of
pregnancy if the fetus were diagnosed with:
a. A surgically correctable heart defect
b. A condition associated with an intellectual deficit
c. A condition associated with infertility
d. A condition associated with severe disabilities and
death within the first year of life
e. A disease that starts after age 40 and progresses
to motor disability
6. Personal reasons for amniocentesis –an open-ended
question: “What were the determining factors that
made you decide to have amniocentesis?” Answers
were examined for common themes and grouped
into several categories. If more than one factor was
mentioned in a single response, they were each
counted separately.Statistics
Statistical analysis was performed using SPSS v19
and included: bivariate Pearson correlations among
level of deliberation, age-risk perception, termination
tolerance and amniocentesis risk perception. Multi-
variate logistic regression was also performed for
these variables, treating level of deliberation as the
dependent variable. Statistical significance was deter-
mined at p ≤ 0.05.
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Questionnaires were analyzed while exploring several topics
to assess different aspects of the decision process and what
affects it. In the following sections, we present objective
knowledge, subjective perceptions and personal reasons, all
of which we expected to influence the decision. These are
followed by presentation of decision “quality” with regard
to informed choice, deliberation and subjective beliefs.
Knowledge measures
Only half of the participants (n = 21) performed the
first trimester screening for DS. A greater number of
participants (n = 32, 76 %) underwent the second tri-
mester serum screening for DS, but about a third of
these participants (n = 11) did not wait for the screen-
ing results before performing amniocentesis. Four par-
ticipants (10 %) had not undergone either of the
screening tests before having amniocentesis.
Participants’ knowledge was evaluated by asking them
to recall several risk estimates relevant to their decision
regarding amniocentesis. Specifically, they were asked
about the results of the two screening tests (if per-
formed), their age related DS risk and the miscarriage
risk associated with amniocentesis. Results for know-
ledge of risk estimates are presented in Table 1.
Participants most often recalled the amniocentesis related
risk, which was explained to them immediately before the
amniocentesis, less than two hours before being inter-
viewed for the study. Almost all participants (93 %) knew
this risk. However, recall for the other risk estimates was
poorer: e.g., only 36 % of the participants who responded to
the question knew their age-related risk. Most participants
knew only their amniocentesis-related risk of miscarriage,
and only one woman knew all the relevant risk estimates.
Do subjective views affect the decision to have
amniocentesis and deliberation over the decision?











amnioAge-risk perception: Participants’ average age related
risk perception was 2.56 (SD = 1.14, on a scale ofe 1 Participants’ knowledge of their risks relevant to the
ion regarding amniocentesis
Correctly recalled result na (%)
rimester screen 11 21 (52 %)
d trimester screen 7 21 (33 %)
elated risk 15 42 (36 %)
ocentesis riskb 39 42 (93 %)
e first and second trimester screens, the percentages are calculated among
who had the test and received results at the time of survey. For age and
centesis related risk, the percentages are calculated among all participants
1:1000 and 1:200 estimates of miscarriage risk associated with
centesis were accepted as correct1-5). Perceived age-related DS risk was significantly
correlated with age (r = 0.52, P < 0.05), so that older
women perceived a higher age related risk. However,
there was no significant difference in age-risk perception
between those who actually knew their age related
risk and those who did not. Thus, women appear
to have a general notion of increased risk with age
even if they lack knowledge of the actual risk level.
Amniocentesis risk perception: Most participants
(n = 35, 83 %) recalled their amniocentesis related
risk. This was a multiple choice question, and
either 1:1000 (the risk cited during counseling) or
1:200 (the risk stated on the consent form) were
accepted as correct). Table 2 presents the
subjective risk perceptions of these participants
who accurately provided risk estimates. Most
participants (66 %) considered the risk associated
with amniocentesis as low, and only 26 % thought
that it was higher than their risk for DS.
b) Deliberation regarding amniocentesis and what
affects it:
More than half the participants (n = 24, 57 %) did not
deliberate over the decision at all, while 18 participants
said they deliberated over the decision either somewhat
(n= 11, 26 %) or very much (n= 7, 17 %). These 18
participants had a lower age-risk perception, and there
was a significant negative correlation between age-risk
perception and degree of deliberation for the entire
sample (r = -0.35, p < 0.05).
Termination tolerance showed a significant negative
correlation with deliberation (r = -0.14, P < 0.05).
Thus, women with a higher tolerance for pregnancy
termination spent less time deliberating over
amniocentesis. Amniocentesis risk perception
(r = 0.17, P = 0.29), age (r = -0.21, P = 0.17), and
number of children (r = 0.23, P = 0.14) were not
significantly correlated with deliberation.
When logistic regression was performed for all the
above mentioned predictor variables with
deliberation (0- none, 1- some or much) as the
dependent variable, only age-risk perception was a
significant predictor (B = -1.15, P < 0.05).
c) Termination tolerance:
Two participants did not reply to this question. The
average termination tolerance score for the remaining
40 participants was 2.5 (SD =1.28) on a scale of 0-5.
Thus, the average participant was willing to consider
termination in half of the presented scenarios. The
most common score was 2 (n = 11) followed by 3
(n = 10) and 1 (n = 9).
As presented in Table 3, five out of 36 respondents
(14 %) answered that they would not terminate the
pregnancy for scenario b (a condition associated
with an intellectual deficit), which corresponds to
Table 2 Subjective risk perceptions of women regarding amniocentesis risk
Question: Replies: Number of women
(percentage of total responders)a
“Do you consider the risk associated
with amniocentesis as high, medium or low?”
Considers risk high 5 (14 %)
Considers risk medium 7 (20 %)
Considers risk low 23 (66 %)
“Which risk do you think is higher, the
risk for DSb or the risk of amniocentesis”
Amniocentesis risk higher than DS risk 9 (26 %)
The two risks are similar 6 (17 %)
Amniocentesis risk lower than DS risk 15 (43 %)
a35 women replied to the first question and 30 to the second
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terminate for the most severe scenario (scenario
d– a condition associated with severe disabilities and
death with the first year of life). One of these two
answered “yes” to scenario b.Personal reasons for amniocentesis
The participants were asked to state their main reason
for undergoing amniocentesis. The most common was
“age”, mentioned by 18 participants (43 %). Additional
reasons were: “wanting certainty” (n = 9, 21 %), “fear of
DS” (n = 6, 14 %) and “doctor's recommendation” or
“medical policy”, mentioned by 5 participants each
(12 %).
Among those who stated “age” as their reason, only
eight participants (45 %) could recall their age related
DS risk. More than half the participants for whom “age”
was the reason for choosing amniocentesis, (n = 11,
61 %), estimated their DS age related risk as “low” or
“very low” regardless of whether they could recall it.
Is the choice regarding amniocentesis informed by the
risk estimates, and is there deliberation?
Knowledge measures of the risk estimates, and delib-
eration levels were used as indicators of an informed
choice.
a) Knowledge of the age-related risk, amniocentesis risk
and at least one DS risk estimate based on serume 3 Distribution of responses for the various termination toleran
rio “Yes” I wo
terminatio
urgically correctable heart defect 6 (14 %)
ondition associated with an intellectual deficit 31 (74 %)
ondition associated with infertility 6 (14 %)
ondition associated with severe disabilities and
within the first year of life
35 (84 %)
isease that starts after age 40 and progresses to motor
ility
22 (52 %)screening were deemed sufficient for informed
choice regarding undergoing amniocentesis. Only
five participants (12 %) knew all of these risks. Fifteen
participants (36 %) knew the two most relevant
risks (age related DS risk and amniocentesis related
pregnancy loss risk). Thus, the majority of women did
not have the necessary knowledge to make a decision
that is informed by risk estimates with regard to
amniocentesis.
b) Degree of deliberation was used as a measure of a
decision that is thoughtfully achieved. Less than half
of the participants deliberated their decision.
There is no significant association between knowledge
scores and amount of deliberation before amniocentesis
(r = -0.095, P = 0.549). Thus, deliberation was independ-
ent from knowledge.
Is the decision concordant with subjective beliefs?
The hypothesis was that women who perceived their
DS risk to be higher than the amniocentesis risk (re-
gardless of whether this perception was true) would
make a decision concordant with their risk perception.
In the entire sample, 18 participants (44 %) perceived a
higher risk of DS, 10 (24 %) perceived a higher risk of
amniocentesis and 7 (16 %) perceived the risks to be
similar (the remaining seven participants did not an-
swer the question). Thus, most participants (60 %) had
a perception of risks that supported their decision toce scenarios (n = 42 total participants)
uld consider
n




34 (81 %) 2 (5 %)
5 (12 %) 6 (14 %)
33 (79 %) 3 (7 %)
2 (5 %) 5 (12 %)
15 (36 %) 5 (12 %)
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claimed that the relative risk of DS as compared with the
miscarriage risk associated with amniocentesis had no ef-
fect on their decision.
Discussion
This study explored whether Israeli AMA women who
elect to undergo amniocentesis without a medical indi-
cation are making an informed choice, i.e., a decision
that is deliberated, and based on relevant information,
both subjective and objective. The results show that, for
the most part, these women disregard the actual risk es-
timates and other medical information when making the
decision to undergo amniocentesis. Most did not delib-
erate before making this decision and claimed that the
risk estimates were irrelevant for their decision. These
results cast doubt on whether these women’s decision to
undergo amniocentesis was indeed fully informed. How-
ever, as many other reasons affect this decision we did
not attempt to explore its subjective “rationality” or val-
idity for these women.
The most common reason participants gave for under-
going amniocentesis was “age” (given by 43 %) but more
than half could not recall their age related DS risk, and
many considered this risk low and thus not representing
an objective age-related reason. It may be that the long-
standing policy, which provides funding for amniocen-
tesis based on age alone, has led women and physicians
to the perception that the government finds it necessary
for women over 35 to undergo amniocentesis. According
to a recent survey, over 60 % of Israeli obstetricians
would recommend amniocentesis to AMA women with
normal screening results [33]. Thus, it may be that phy-
sicians’ recommendations also follow the age based
funding policy, so that women who followed their physi-
cians’ recommendation were in fact being guided by the
government policy. This suggestion is somewhat sup-
ported by the finding that five participants (12 %) specif-
ically cited “public policy” as their reason for
amniocentesis, and another five (12 %) cited “physician
recommendation” as their reason for amniocentesis.
In a previous study (16) we interviewed AMA and
young women (without a medical indication for amnio-
centesis) and found that the majority of AMA women
had amniocentesis while citing “age” as their main rea-
son for the test. These women also exhibited low levels
of knowledge of the relevant risk estimates. Younger
women however, rarely chose to have amniocentesis and
had better knowledge of the relevant risks. These finding
support our suggestion that there is a widespread per-
ception that age ≥35 is by itself a reason to have amnio-
centesis regardless of other factors.
Some elements of an informed decision were evident:
many participants believed that their DS risk was higherthan the risk of amniocentesis, thus constituting subject-
ive justification for having the procedure. In addition,
most participants stated that they would consider ter-
mination of a pregnancy affected with intellectual dis-
ability, consistent with the notion that the purpose of
amniocentesis is to diagnose fetuses with DS and pro-
vide an option to terminate these pregnancies. However,
concordance of a decision with subjective views and be-
liefs is not equivalent to an informed decision, such that
is based on risk estimates, as the belief that the risk of
DS is higher than the risk of amniocentesis was not
based on the actual risk levels.
The results are in general agreement with the findings
of Vergani et al. [34] who reported that the key deter-
minant of the choice to have amniocentesis among
AMA women (whether they had the procedure or not)
is the a priori opinion of the woman towards the pro-
cedure. Most participants seemed to have had a prede-
termined decision, and deliberated little about it during
pregnancy, irrespective of their actual risk estimates.
Notably, women may have other reasons for amnio-
centesis, and the magnitude of DS risk is only one of
their considerations. This small-scale study did not ex-
plore participants’ views on having a child with disability
and the relative burden of raising such a child in com-
parison to losing a pregnancy due to miscarriage. It is
possible that some women consider the possibility of a
DS child as unacceptable and are not willing to take any
risk of it happening, thus performing amniocentesis re-
gardless of their risk level. This issue warrants further
exploration in a larger study.
The findings show that while most participants had
tests that would provide screening information regarding
DS risk, a considerable portion of them did not wait for
the test results before going ahead with amniocentesis.
This suggests that women do not consider screening
tests as necessary to inform their decision regarding am-
niocentesis, and some women decide not to undergo the
screening tests at all, as they have already decided to
undergo amniocentesis, mostly due to “age”, but also
due to a desire for certainty, fear of DS, and physician
recommendations. Given the relative lack of deliberation
and consideration of risks associated with the procedure,
policy makers should consider whether sweeping fund-
ing for amniocentesis for AMA women sends the mes-
sage that the procedure is warranted and without risk.
In this context, promoting shared decision making
(SDM) in the Israeli health system as stated by Miron-
Shatz et al. [35] may be important. Promoting SDM has
also been previously suggested as a way to reduce
healthcare costs [1].
The present study has several limitations. The sample
was relatively small, featuring 42 women from one med-
ical center, who were not fully representative of the
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sonably represents a large segment of secular, educated,
Israeli women who utilize many prenatal tests, as was
found by the Ministry of Health survey [17]. The
Ministry of Health survey shows that while there is no
significant difference in utilization of other prenatal
tests between AMA and younger women, the difference
regarding amniocentesis is striking. However, the exten-
sive survey conducted by the Ministry of Health did
not address women’s reasons to pursue various tests,
nor did that survey evaluate the results of these tests so
that the actual risk levels of the women that did or did
not have amniocentesis are unknown. Due to the small
size of the sample in the present study, we cannot as-
sume generalizability to the entire Israeli population, so
it may be valuable to address this in a future nation-
wide survey. Another limitation is that the present
study only examined women who had amniocentesis.
Future work should also explore the factors influencing
decision-making in women who did not have the pro-
cedure, thereby allowing a comparison between the two
groups.
New technologies, such as noninvasive testing for fetal
trisomy and microarray-based techniques, have recently
been introduced into the prenatal testing field. Many
technologies are offered directly to consumers under the
premise that the consumers can make informed deci-
sions about them. However, our findings cast doubt on
whether women take into account all risk estimates
available to them in such circumstances. The integration
of these technologies into existing practices should be
designed to address these issues by both the medical
community and policy makers.Conclusions
The results of this study cast doubt on whether the deci-
sion to undergo amniocentesis after age 35 is fully in-
formed by risk estimates among women that had the
procedure. The longstanding policy which provides
funding for amniocentesis based on age alone may have
led to the conception that being over 35 is, in and of it-
self, a sufficient reason to undergo amniocentesis. Thus
most women do not deliberate before having the proced-
ure, and some go through the motions of DS screening,
but do not take the results into account when deciding
to undergo amniocentesis.
This information is significant for policymakers as it
emphasizes the link between public funding and the
choices of individual women, and thus has implications
for allocation of healthcare expenditures.Competing interests
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